Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Biocartis, Co-Diagnostics, Blueprint Medicines, Celogics, More

NEW YORK – Biocartis this week reported first quarter product revenues of €10.1 million ($11.0 million), up 17 percent from €8.6 million in Q1 2021. The Mechelen, Belgium-based molecular diagnostics firm booked revenues of €6.7 million for oncology testing, an increase of 42 percent year over year. However, year-over-year COVID-19 testing product revenues fell by half, and cartridge revenues for infectious disease testing overall fell to 10 percent of total product revenues, the firm said.

Meanwhile, the installed base of Biocartis' fully automated, real-time PCR-based Idylla instrument grew to 2,000 in the recently completed quarter. The average sales price per cartridge for oncology testing was €114 and for all products €101. The firm noted that during the quarter, it continued with the ramp-up of a fully automated manufacturing line and transferred the manufacturing of Idylla SARS-CoV-2 products to it. Biocartis had €37.3 million in cash at the end of Q1. The company anticipates full-year product revenues of €50 million to €55 million, up 24 percent to 36 percent over full-year 2021.

Co-Diagnostics said this week that India's Central Drugs Standard Control Organization has cleared the Saraq Hepatitis C Viral Load kit from CoSara Diagnostics, Co-Diagnostics' joint venture for manufacturing and sales in India. The real-time PCR test for HCV leverages Co-Diagnostics' CoPrimer technology and is for use as an aid to assess response to antiviral treatments for the virus.

The Access to Comprehensive Genomic Profiling Coalition (ACGP) said this week that it has added Blueprint Medicines to its coalition of companies advocating for payors to cover comprehensive genomic profiling (CGP) for advanced cancer patients. As part of its advocacy efforts, the coalition educates health insurers and other stakeholders across healthcare about CGP's clinical utility and economic value. ACGP considers any company that either offers CGP tests or offers products with CGP as eligible for potential coalition membership. Current members also include Labcorp, Exact Sciences, Invitae, Roche, Thermo Fisher Scientific, Strata Oncology, Tempus, Illumina, Foundation Medicine, NeoGenomics, and PGDx.

Celogics has inked an exclusive license to distribute globally Nexel’s Cardiosight-S, a human iPSC-derived cardiomyocyte product line, for the life sciences research market. Seattle-based Celogics also said that it plans to build a 20,000-square-foot biomanufacturing facility and new headquarters nearby in Mukilteo, Washington, which include labs custom designed for iSPC cell culture and related products.

Applied Cells and Stemcell Technologies Canada said this week that they are collaborating to develop a high-performance cell separation solution that combines Applied Cells' MARS platform with Stemcell's EasySep immunomagnetic cell separation kits. The partnership is intended to help researchers automate and increase the efficiency of isolating high-quality cells from a wide range of sample types including blood, bone marrow, apheresis products, and dissociated tissue, the companies said.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.